Nocturia News and Research

RSS
Symptom relief at the core of prostate patient management

Symptom relief at the core of prostate patient management

Botulinum toxin effective in treating OAB among women

Botulinum toxin effective in treating OAB among women

European Urology to launch two new Resource Centres

European Urology to launch two new Resource Centres

More of saw palmetto does not reduce urinary symptoms related to BPH

More of saw palmetto does not reduce urinary symptoms related to BPH

Urologic Nursing publishes NAFC nocturia research in middle-aged American women

Urologic Nursing publishes NAFC nocturia research in middle-aged American women

Genetic factors can explain people's susceptibility to urinary incontinence

Genetic factors can explain people's susceptibility to urinary incontinence

Patients with BPE may have Obstructive Sleep Apnea

Patients with BPE may have Obstructive Sleep Apnea

New study: Circadian system may contribute to daily pattern of vasovagal syncope

New study: Circadian system may contribute to daily pattern of vasovagal syncope

XYTOS shares cancer patient treatment results

XYTOS shares cancer patient treatment results

Allergan second-quarter diluted EPS increases to $0.78

Allergan second-quarter diluted EPS increases to $0.78

SWHR hosts briefing on urinary incontinence, overactive bladder

SWHR hosts briefing on urinary incontinence, overactive bladder

SPET-085 is effective in blocking critical enzyme that leads to BPH: Study

SPET-085 is effective in blocking critical enzyme that leads to BPH: Study

Nymox reports positive new results from pooled analysis of NX-1207 clinical trials for BPH

Nymox reports positive new results from pooled analysis of NX-1207 clinical trials for BPH

CPEX Pharmaceuticals reports record quarterly royalty revenues from Testim sales

CPEX Pharmaceuticals reports record quarterly royalty revenues from Testim sales

NAFC holds free educational webinar for seniors who live with incontinence

NAFC holds free educational webinar for seniors who live with incontinence

CPEX Pharmaceuticals files definitive proxy materials with SEC, mails open letter to shareholders

CPEX Pharmaceuticals files definitive proxy materials with SEC, mails open letter to shareholders

Serenity Pharmaceuticals enters agreement with Allergan for nocturia product candidate

Serenity Pharmaceuticals enters agreement with Allergan for nocturia product candidate

Allergan, Serenity Pharmaceuticals announce global agreement for nocturia drug development

Allergan, Serenity Pharmaceuticals announce global agreement for nocturia drug development

CPEX Pharmaceuticals' fourth-quarter 2009 revenues up 23%

CPEX Pharmaceuticals' fourth-quarter 2009 revenues up 23%

Vantia Therapeutics initiates Phase IIb trial of VA106483 for nocturia

Vantia Therapeutics initiates Phase IIb trial of VA106483 for nocturia